Only logged-in users can see full content details
ZAGREB, May 14
(Hina) - Denmark's Xellia Pharmaceuticals, a
specialty pharmaceutical company focusing on providing important
anti-infective treatments against serious and often life-threatening
infections, on Wednesday announced it had invested US$ 2 million
(approx. HRK 11.5 million) to significantly expand its Product and
Innovation R&D Centre of Excellence in Zagreb.